LQDA: Liquidia Technologies Company Value to Net Income

Corporate emblem and logo of Liquidia Corp (LQDA)

The price-to-earnings trend for Liquidia Corporation (LQDA) reflects expectations regarding the commercialization of Yutrepia for the treatment of pulmonary hypertension. The value of -54.30 captures the magnitude of this parameter. Business development relies on U.S. drug delivery centers. Asset stability is ensured by patent protection for inhalation methods, creating significant potential for profit growth driven by the ease of drug administration.

LQDA Liquidia Inc.: Price to Earnings Ratio in the range 07/04/2022 - 11/15/2026

Comprehensive metric breakdowns and analytics for Liquidia Corp (LQDA)

- price and consensus price forecast:
Comprehensive company analysis:Liquidia Corp - LQDA
Flagship merchandise of Liquidia

The P/E ratio reflects the market value of a single unit of net profit, allowing an investor to determine the extent of an asset's overvaluation or its potential undervaluation. Analyzing the estimated P/E of Liquidia Corporation (LQDA) helps align current market expectations with the lengthy certification timelines for proprietary drugs, where the risk of clinical trial failure directly impacts the fair valuation multiple of the business.

Analysis of competing companies

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Galapagos Genomics - Company Value to Net Income|ANIP (ANI Pharmaceuticals Inc) - P/E Multiple|Market Cap to Earnings mannkindcorp.com MNKD|Price to Earnings Ratio Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX (Pacira Pharmaceuticals) - Company Value to Net Income|P/E Multiple SPRY (ARS Pharmaceuticals Inc)|Market Price to Net Income Ratio TBPH (Theravance)|AQST - Price to Earnings Ratio|scPharmaceuticals (SCPH) - Price to Earnings Ratio|TECX: P/E Multiple|Price to Earnings Multiple TNXP|Price to Earnings Ratio China SXT Pharmaceuticals, Inc.|EPRX: Company Value to Net Income|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)